**Background**
CD47 is a transmembrane protein widely expressed on the surface of various cells, including healthy cells and tumor cells. It acts as a “don’t eat me” signal by interacting with signal regulatory protein alpha (SIRPα) on macrophages, thereby inhibiting phagocytosis and allowing cancer cells to evade the innate immune system. This immune evasion mechanism is a critical factor in tumor progression and metastasis across various malignancies. Consequently, blocking the CD47-SIRPα axis has emerged as a promising therapeutic strategy to enhance macrophage-mediated clearance of tumor cells. In this context, we will introduce an Anti-CD47 Antibody description – Anti-CD47 Antibody (B6.H12).
**Definition**
Anti-CD47 Antibody (B6.H12) is a mouse IgG1 κ chimeric antibody that specifically targets human CD47 to block its interaction with SIRPα.
**In Vitro and In Vivo Studies**
The Anti-CD47 Antibody biological activity has been extensively evaluated across multiple cancer models. In vitro, Anti-CD47 Antibody (B6.H12) (10 μg/mL, 2 h) significantly increases the macrophage phagocytosis of HepG2, H3B, meningioma, and osteosarcoma tumor cells. Furthermore, it demonstrates potent inhibitory effects on tumor cell behavior; specifically, it decreases the proliferation of IOMM-Lee cells (10 μg/mL, 2 h) and attenuates their migration and invasion abilities (10 μg/mL, 24 h). In osteosarcoma cells, a concentration of 100 μg/mL over 5 days significantly decreases invasion. Notably, the antibody (1.1-10 μg/mL, 24-72 h) is not cytotoxic to normal hepatocytes or human hepatocellular carcinoma cells.
Regarding Anti-CD47 Antibody in vivo performance, the antibody shows potent anti-tumor effects in various xenograft models. In heterotopic and orthotopic tumor mice models, administration of 400 μg (i.p., twice weekly) inhibited tumor growth and increased the intra-tumor migration of macrophages. In nude mice injected with IOMM-Lee cells, 100 μg (i.p., daily for 5 weeks) resulted in significantly smaller tumor volumes. Additionally, in osteosarcoma mice models, 100 μg (i.p., three times weekly) inhibited tumor progression and reduced the incidence of spontaneous metastasis. In conclusion, Anti-CD47 Antibody (B6.H12) is a powerful tool for Anti-CD47 Antibody Cancer research, effectively promoting phagocytosis and inhibiting tumor growth.
Keywords
Anti-CD47 Antibody (B6.H12), CD47, Cluster of Differentiation 47, MER6, OA3, SIRPα, Proliferation, Macrophage, Cancer, Osteosarcoma, IOMM-Lee, Inhibitor, inhibitor, inhibit
References
[1] Xiao Z, et al. Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. Cancer Lett. 2015 May 1;360(2):302-9.
[2] Liu X, et al. Tumor-selective Blockade of CD47 Signaling with CD47 Antibody for Enhanced Anti-tumor Activity in Malignant Meningioma. Curr Neuropharmacol. 2023;21(10):2159-2173.
[3] Xu JF, et al. CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models. Oncotarget. 2015 Sep 15;6(27):23662-70.